Evergrowth BioHealthcare Capital’s Post

Stop Macular Degeneration: Best Tips for Preventing Vision Loss Imagine slowly losing the ability to see the faces of loved ones, or the world around you gradually fading into a blur. For millions suffering from macular degeneration, this is a harsh reality. But there's hope on the horizon. Advances in biotech are bringing new treatments and even potential cures closer than ever. Innovations like gene therapy, stem cell treatments, and advanced pharmaceuticals are giving patients hope for a brighter, clearer future. As we continue to fight this degenerative condition, we invite you to be part of the solution. Evergrowth Biohealthcare Capital supports biotech companies at the forefront of research, including that of macular degeneration—companies that are pioneering life-changing treatments and helping restore vision to those in need. https://buff.ly/3N8dOGz If you're an accredited investor and wanting to learn more, click this Calendly link to schedule a free consultation call with Dr. Harvey Tran https://buff.ly/3XQnJWl You can also schedule a call by scanning the QR code above with your mobile phone. Disclaimer: This content is for informational purposes only and should not be considered financial advice. Investing in biotechnology involves risks, and investors should conduct their own research before making any investment decisions.

Latest DON Therapeutics news The future of healthcare is being transformed by groundbreaking advancements in gene therapy, cell therapy, and immunotherapy. These innovative treatments are pushing the boundaries of what's possible in medicine. By harnessing the power of genetic material, living cells, and the body's immune system, we can now target the root causes of diseases with unprecedented precision. Gene therapy offers the potential to repair or replace faulty genes, addressing genetic disorders at their core. Cell therapy utilizes living cells to regenerate and repair damaged tissues and organs, opening new frontiers in treating a wide range of conditions. Immunotherapy leverages the immune system to fight cancer and other diseases, creating highly targeted treatments with fewer side effects. Together, these therapies represent a new era in personalized medicine, offering hope and healing to millions worldwide. The convergence of these technologies is set to change the landscape of healthcare, making once-unthinkable treatments a reality. More about DON Therapeutics: https://lnkd.in/eKs-9g9e We are always looking for new healthcare opportunities. Submit your opportunity: https://lnkd.in/dJfhwVvv #biotech #seriesa #seriesb #healthcare #genetherapy #celltherapy #funding

🚀 Cell Revolution – Gene Therapy and Regenerative Medicine Regulatory Trends Online Forum. Our next speaker, Dr. Cheng-Hsien Tsai (Chris Tsai), CEO of Bionet. Dr. Tsai stated that Taiwan and Japan share a similar regulatory framework, and Taiwan has built a particularly mature system for cell therapy regulations. The recently passed Regenerative Medicine Act in Taiwan advances medical science and technology while lowering costs to benefit patients. Many countries have established regulations for extracellular vesicles. Taiwan, recognizing the potential of these therapies, is developing its regulatory framework to support their advancement. This effort advances the development and commercialization of regenerative medicine products, positioning Taiwan as a leader in cutting-edge medical technologies. The integration of precision medicine and next-generation sequencing (NGS) into these frameworks further bolsters Taiwan’s leadership. Precision medicine, powered by NGS, allows for highly personalized treatments that improve patient outcomes. Continuous regulatory evolution ensures Taiwan remains at the forefront, fostering global biomedical innovation and collaboration, and driving advancements in precision medicine and NGS applications. #ngs #precisionmedicine #celltherapy #gene #onlineforum

🔬✨ Exciting Developments in Gene Therapy! ✨🔬 A promising CRISPR-based therapy is making waves in the fight against inherited blindness disorders. The BRILLIANCE trial, led by Harvard Medical School's Massachusetts Eye and Ear, has shown significant improvements in vision for 79% of participants with a rare inherited retinal disease called Leber congenital amaurosis (LCA) Type 10. 🌟 Key Highlights: 🔹 EDIT-101 Therapy: Developed by Editas Medicine, this CRISPR-Cas9 gene-editing drug targets the CEP290 gene mutation associated with LCA. 🔹 Phase I/II Trial: Demonstrated safety and efficacy, with 11 out of 14 participants showing vision improvements in at least one of four measured outcomes. 🔹 Groundbreaking Results: Participants reported enhanced visual acuity, improved navigation abilities, and a better quality of life. Six participants showed improvement in two or more outcomes. 💡 Innovative Approach: The CRISPR-Cas9 technology acts like molecular scissors, precisely editing the mutation directly within the human body through a subretinal injection, restoring the function of crucial light-sensing cells. 👁️🗨️ Incredible Impact: "To hear from several participants how thrilled they were that they could finally see the food on their plates — that is a big deal," said Eric Pierce, the corresponding author of the study. These life-changing outcomes underscore the potential of CRISPR gene therapy in treating inherited vision loss. #CRISPR #GeneTherapy #Biotechnology #Innovation #Blindness #LCA #MedicalResearch #EditasMedicine #HarvardMedicalSchool #VisionRestoration #HealthcareInnovation #BiotechBreakthroughs

Is Regenerative Medicine Set to Transform Healthcare by 2032? The global regenerative medicine market, valued at USD 34.56 billion in 2023, is set for remarkable growth with a projected CAGR of 32.4% from 2024 to 2032. By 2032, the market is expected to reach USD 398.77 billion, reflecting the increasing adoption of advanced therapies such as stem cell treatments, gene editing, and tissue regeneration. The potential for these therapies to treat complex conditions like neurological disorders, heart disease, and joint degeneration is driving a surge in investment and innovation in the sector. Explore more insights with the free sample PDF here: https://lnkd.in/d8w3ijSP #regenerativemedicine #stemcells #biotechnology #healthcareinnovation #medtech

This year’s ESACT was a great snapshot of a rapidly evolving cell and gene therapy (CGT) industry. Our experts Andrea Vervoort, Keara Sutherland, and Oliver Varette highlight 3 standout conference insights: ✔ The need for viral vectors is expected to continue to grow. This necessitates efficient and economical manufacturing methods to meet rising demand while also being mindful of environmental footprints. ✔ Industry leveraging AI/ML to model and optimize manufacturing processes, predict optimal outcomes and improve efficiency. Marinna Madrid, presented an AI/ML model for the automated production of stem cells for personalized regenerative cell therapies. There is also an emphasis on curating datasets and minimizing data silos within organizations. ✔ An excellent talk by Cath Green highlighted the benefits of providing robust biomanufacturing capabilities to academics. This enables important research to reach clinical trials, which is crucial for scenarios such as pandemics. Integrating industry and academia is pivotal for accelerating innovative therapies. Ultimately, CGT manufacturing is undeniably complex, and industry and academia collaboration is the cornerstone for the CGT sector to take transformative strides. #biomanufacturing #ESACT2024 #innovation

I explore the diverse applications of nanotechnology in a range of healthcare settings in my most recent literature review. I examine how non-viral nanostructures, which greatly reduce immune responses and off-target modifications, are providing safer alternatives in gene therapy. The study delves into the novel application of nanoparticles in gene silencing, where innovations are producing impressive tumor suppression and successful therapies for ailments such as rheumatoid arthritis. Furthermore, the promise of nanosystems for precise medication delivery, ocular illness treatment, and brain disorder treatment through blood-brain barrier bridging is emphasized. Despite these encouraging advancements, the review also highlights the drawbacks and restrictions of nanotechnology, including toxicity issues and the need for deeper comprehension of in vivo behaviors.

𝐒𝐭𝐞𝐦 𝐂𝐞𝐥𝐥 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞 𝐏𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $𝟐𝟏.𝟖 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟐𝟖 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐚𝐭 https://lnkd.in/d-KbXnRJ The global stem cell manufacturing market in terms of revenue was estimated to be worth $12.7 billion in 2023 and is poised to reach $21.8 billion by 2028, growing at a CAGR of 11.3% from 2023 to 2028. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Cell and Gene Therapy Catapult Cell-Easy Cell BioEngines, Inc Cell Therapy Group Cell Cure Neurosciences Ltd. Cell X Technologies Stem Cell Cluster Stem Sel Srl Stem Cell Reserve Akron Bio Nodexus Inc. Nexcelom    Axion BioSystems       #StemCellResearch, #RegenerativeMedicine, #StemCellTherapy, #Biotech, #CellTherapy, #StemCellScience, #TissueEngineering, #Bioengineering, #MedicalInnovation, #Biopharma #stemcellmanufacturingmarket #stemcellmanufacturing

Take a look at our review article! https://lnkd.in/eSw4ki-U In this review, we explore gene delivery as a promising therapeutic avenue for TBI. By facilitating the production of beneficial biologics within the brain, gene delivery could revolutionize treatment approaches, offering hope for better long-term outcomes. The review delves into: - The potential of gene delivery in TBI treatment. - Promising vectors and key delivery routes. - Target pathways for improving patient outcomes. - The challenges and health economics surrounding gene delivery for TBI. #TraumaticBrainInjury #GeneDelivery #Neuroinflammation #HealthcareInnovation #AilaBiotech